BBV87 Chikungunya Vaccine Description
Bharat Biotech International Ltd's (BBIL) Chikungunya vaccine candidate (BBV87) is an inactivated whole virion vaccine based on a strain derived from an East, Central, South African (ECSA) genotype. Based on the ECSA strain, BBIL developed a pure, inactivated CHIKV immunogenic formulation. BBV87 vaccine completed standard pre-clinical studies, and the adjuvanted vaccine elicited an optimum immune response in phase 1 clinical trials in India.
On August 24, 2023, the International Vaccine Institute (IVI) announced the first participant received BBV87 in a Phase II/III clinical trial in Costa Rica, marking the start of a multi-country study funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology, India. In addition to the trial at Clinica San Agustin in Costa Rica, trials are expected to begin in Panama and Colombia by September 2021 and in Thailand and Guatemala soon after.
On June 15, 2023, MDPI published: An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine. This review gives an overview of the outbreak history and CHIKV-related research in India to favor novel; high-quality research works that promote effective treatment and preventive strategies, including vaccine development, against CHIKV infection.
Inactivated virion technology has a safety profile that potentially makes this vaccine accessible to special populations, such as immunocompromised and pregnant women, that some other technologies cannot reach.
The first report on CHIKV was from Tanzania, an eastern African country, in 1952. The first CHIKV outbreak in India was recorded in the city of Kolkata in 1963. Chikungunya is an emerging arthritogenic arboviral illness caused by the chikungunya virus (CHIKV), a member of the genus Alphavirus in the Togaviridae family. The pathologic mechanism of this virus leads to acute infection of several weeks, which can persist for months with an incubation period of 2–12 days. The hallmark characteristics of CHIKV infection are saddle-back fever, polyarthralgia (mainly in small joints – ankles, toes, wrists, and phalanges), and a petechial or maculopapular rash (mainly on the face, limbs, and trunk). CHIKV affects all age groups with dengue-like symptoms characterized by nausea, fever, chills/rigors, headache, polyarthralgia, myalgia, photophobia, and skin rash.
Bharat Biotech creates innovative vaccines and bio-therapeutics trusted by physicians around the world. USFDA, KFDA, and WHO approve BBIL's manufacturing facilities.
BBV87 Chikungunya Vaccine Indication
Chikungunya virus was first identified in Tanzania in 1952, with sporadic disease outbreaks reported across Africa and Asia. In 2004, the disease began to spread quickly, causing large-scale outbreaks worldwide. Since the re-emergence of the virus, the total number of cases has been estimated at over 3.4 million in 43 countries. Outbreaks during the last decade worldwide have prompted the National Institute of Allergy and Infectious Diseases (NIAID) to add CHIKV to the category C priority pathogen biodefense list.
BBV87 Chikungunya Vaccine Dosage
A 2-dose live-inactivated vaccine (BBV87) against Chikungunya is being tested.
BBV87 Chikungunya Vaccine News
June 3, 2020 - The Coalition for Epidemic Preparedness Innovations (CEPI) announced a new partnering agreement to advance the development of a Chikungunya vaccine. The CEPI will provide the consortium up to US $14.1 million for vaccine manufacturing and clinical development of a 2-dose live-inactivated vaccine (BBV87) against Chikungunya. The European Union's Horizon 2020 program supports the funding through an existing framework partnership agreement with CEPI. The consortium was also supported with a grant of up to US $2.0 million from the Indian Government's Ind-CEPI initiative to fund the set-up of GMP manufacturing facilities for the vaccine in India and subsequent manufacture of clinical trial materials.
June 2, 2020 - Oslo, Norway; Seoul, South Korea; Telangana, India—CEPI, in collaboration with Ind-CEPI, has announced a new partnering agreement with a consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) to advance the development of a Chikungunya vaccine.
BBV87 Chikungunya Vaccine Clinical Trial
The BBV87 vaccine candidate completed pre-clinical studies, and an optimum immune response was elicited by the adjuvanted vaccine in phase 1 clinical trials in India.
A Phase II/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety And Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 Years in Latin America and Asia.
